Development of Pyrazine-Anilinobenzamides as Histone Deacetylase HDAC1-3 Selective Inhibitors and Biological Testing Against Pancreas Cancer Cell Lines

Methods Mol Biol. 2023:2589:145-155. doi: 10.1007/978-1-0716-2788-4_10.

Abstract

Class I histone deacetylase (HDAC) enzymes are key regulators of cell proliferation and are frequently dysregulated in cancer cells. Here we describe the synthesis of a novel series of class-I selective HDAC inhibitors containing anilinobenzamide moieties as ZBG connected with a central (piperazin-1-yl)pyrazine moiety. Compounds were tested in vitro against class-I HDAC1, 2, and 3 isoforms. Some highly potent HDAC inhibitors were obtained and were tested in pancreatic cancer cells and showed promising activity. Moreover, we summarize how the growth-inhibitory effects of these compounds can be determined in murine pancreatic cancer cell lines.

Keywords: Anilinobenzamides; Capping group; Class-I histone deacetylases inhibitors; HDAC; Pancreas cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cell Proliferation
  • Histone Deacetylase 1 / metabolism
  • Histone Deacetylase Inhibitors* / pharmacology
  • Histone Deacetylases / metabolism
  • Humans
  • Mice
  • Pancreatic Neoplasms* / drug therapy
  • Protein Isoforms / metabolism
  • Pyrazines / pharmacology
  • Structure-Activity Relationship

Substances

  • Histone Deacetylase Inhibitors
  • Pyrazines
  • Histone Deacetylases
  • Protein Isoforms
  • HDAC1 protein, human
  • Histone Deacetylase 1